中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 37 Issue 2
Mar.  2021
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(2): 433-436

Advances in the models for predicting the risk of liver cancer during antiviral therapy in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2021.02.039

  • Department of Hepatology and Gastroenterology, The Third Central Clinical College of Tianjin Medical University; Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases; Artificial Cell Engineering Technology Research Center; Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China

  • Received Date: 2020-08-03
  • Accepted Date: 2020-09-15
  • Published Date: 2021-02-20
    Abstract
  • Hepatitis B virus infection is one of the primary causes of liver cirrhosis and liver cancer. The use of antiviral drugs significantly reduces the risk of liver cancer in patients with chronic hepatitis B (CHB), but some of the patients who receive antiviral drugs for a long time still develop liver cancer. Therefore, it is necessary to early identify and predict the risk of liver cancer in such patients. Currently, several models for predicting the risk of liver cancer during antiviral therapy in CHB patients have been developed based on the risk factors such as liver cirrhosis, age, sex, liver stiffness, virology, serological markers, alcohol consumption, and history of diabetes, including REACH-B, PAGE-B, mPAGE-B, APA-B, CAMD, AASL, and REAL-B. This article reviews the research advances in the models for predicting the risk of liver cancer during antiviral therapy in CHB patients.

     

    • FullText(HTML)
    • References(30)
  • [1]
    Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2017, 3(4): 524-548.
    [2]
    FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2
    [3]
    FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48(2): 335-352. DOI: 10.1016/j.jhep.2007.11.011
    [4]
    CHAN SL, WONG VW, QIN S, et al. Infection and cancer: The case of hepatitis B[J]. J Clin Oncol, 2016, 34(1): 83-90. DOI: 10.1200/JCO.2015.61.5724
    [5]
    LIU K, CHOI J, LE A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis[J]. Aliment Pharmacol Ther, 2019, 50(9): 1037-1048. DOI: 10.1111/apt.15499
    [6]
    WONG GL, WONG VW. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy[J]. World J Gastroenterol, 2013, 19(39): 6515-6522. DOI: 10.3748/wjg.v19.i39.6515
    [7]
    ARENDS P, SONNEVELD MJ, ZOUTENDIJK R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians[J]. Gut, 2015, 64(8): 1289-1295. DOI: 10.1136/gutjnl-2014-307023
    [8]
    SERPER M, TADDEI TH, MEHTA R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality[J]. Gastroenterology, 2017, 152(8): 1954-1964. DOI: 10.1053/j.gastro.2017.02.040
    [9]
    KIM BH, LIM YS, KIM EY, et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population[J]. J Gastroenterol Hepatol, 2018, 33(2): 475-483. DOI: 10.1111/jgh.13848
    [10]
    European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
    [11]
    TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800
    [12]
    OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370.
    [13]
    Korean Association for the Study of the Liver. KASL clinical practice guidelines: Management of chronic hepatitis B[J]. Clin Mol Hepatol, 2016, 22(1): 18-75. DOI: 10.3350/cmh.2016.22.1.18
    [14]
    CADIER B, BULSEI J, NAHON P, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States[J]. Hepatology, 2017, 65(4): 1237-1248. DOI: 10.1002/hep.28961
    [15]
    CHANG TT, LAI CL, KEW YOON S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology, 2010, 51(2): 422-430. DOI: 10.1002/hep.23327
    [16]
    LAI CL, GANE E, LIAW YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B[J]. N Engl J Med, 2007, 357(25): 2576-2588. DOI: 10.1056/NEJMoa066422
    [17]
    MARCELLIN P, HEATHCOTE EJ, BUTI M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J]. N Engl J Med, 2008, 359(23): 2442-2455. DOI: 10.1056/NEJMoa0802878
    [18]
    LEE HW, YOO EJ, KIM BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy[J]. Am J Gastroenterol, 2014, 109(8): 1241-1249. DOI: 10.1038/ajg.2014.157
    [19]
    JUNG KS, KIM SU, SONG K, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy[J]. Hepatology, 2015, 62(6): 1757-1766. DOI: 10.1002/hep.28115
    [20]
    PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016, 64(4): 800-806. DOI: 10.1016/j.jhep.2015.11.035
    [21]
    KIM JH, KIM YD, LEE M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol, 2018, 69(5): 1066-1073. DOI: 10.1016/j.jhep.2018.07.018
    [22]
    CHEN CH, LEE CM, LAI HC, et al. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir[J]. Oncotarget, 2017, 8(54): 92431-92441. DOI: 10.18632/oncotarget.21369
    [23]
    HSU YC, YIP TC, HO HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B[J]. J Hepatol, 2018, 69(2): 278-285. DOI: 10.1016/j.jhep.2018.02.032
    [24]
    YU JH, SUH YJ, JIN YJ, et al. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir[J]. Eur J Gastroenterol Hepatol, 2019, 31(7): 865-872. DOI: 10.1097/MEG.0000000000001357
    [25]
    YANG HI, YEH ML, WONG GL, et al. Real-world effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy[J]. J Infect Dis, 2020, 221(3): 389-399. DOI: 10.1093/infdis/jiz477
    [26]
    WU S, KONG Y, PIAO H, et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis[J]. Liver Int, 2018, 38(6): 1045-1054. DOI: 10.1111/liv.13623
    [27]
    CHIANG HH, LEE CM, HU TH, et al. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir[J]. Liver Int, 2018, 38(11): 1997-2005. DOI: 10.1111/liv.13889
    [28]
    WONG GL, CHAN HL, TSE YK, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B[J]. J Hepatol, 2018, 69(4): 793-802. DOI: 10.1016/j.jhep.2018.05.009
    [29]
    KIM BG, PARK NH, LEE SB, et al. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B[J]. Liver Int, 2018, 38(12): 2269-2276. DOI: 10.1111/liv.13938
    [30]
    HSU YC, JUN T, HUANG YT, et al. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2018, 48(10): 1128-1137. DOI: 10.1111/apt.15006
    • Relative Articles

  • Relative Articles

    [1]Shanshan XU, Lixia QIU, Yali LIU, Jing ZHANG. Risk factors and predictive models for liver cancer after sustained virologic response in hepatitis C[J]. Journal of Clinical Hepatology, 2024, 40(6): 1259-1263. doi: 10.12449/JCH240629
    [2]Yichen ZHU, Chunxia SHA, Chunsun FAN, Tiejun ZHANG. Risk factors for liver cancer in chronic hepatitis B patients and construction of a nomogram prediction model[J]. Journal of Clinical Hepatology, 2024, 40(12): 2441-2449. doi: 10.12449/JCH241214
    [3]Xiaoyan MA, Yun CHEN, Jiacheng LIU, Jie LI, Chao WU. Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis[J]. Journal of Clinical Hepatology, 2023, 39(1): 63-69. doi: 10.3969/j.issn.1001-5256.2023.01.010
    [4]Jingyi ZHANG, Yingmei TANG, Jiaqi LI, Qian WANG, Chenrui ZHANG. Risk factors for osteopenia/osteoporosis and the diagnostic value of CT value in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(5): 1041-1047. doi: 10.3969/j.issn.1001-5256.2022.05.013
    [5]Bin WANG, Hansheng LIANG, Yi FENG, Youzhong AN. Risk factors for perioperative hypotension in severe patients after liver cancer surgery[J]. Journal of Clinical Hepatology, 2022, 38(3): 572-576. doi: 10.3969/j.issn.1001-5256.2022.03.015
    [6]Jiajia RUAN, Shifei WEN, Xia WANG, Li LI, Juanjuan FU, Xiucheng PAN. Influencing factors for recompensation in patients with first-time decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1796-1800. doi: 10.3969/j.issn.1001-5256.2022.08.015
    [7]Yu LIU, Xue MEI, Yuyi ZHANG, Ying ZOU, Zhengguo ZHANG, Hongying GUO, Wei YUAN, Jiefei WANG, Zhiping QIAN. Clinical features and risk factors of acute hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2021, 37(3): 565-569. doi: 10.3969/j.issn.1001-5256.2021.03.013
    [8]Long LIU, Ke SHI, Qun ZHANG, Chongping RAN, Jie HOU, Yi ZHANG, Xianbo WANG. Risk factors for hepatocellular carcinoma in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(7): 1589-1593. doi: 10.3969/j.issn.1001-5256.2021.07.022
    [9]He CHEN, Juanjuan FU, Li LI, Guangde YANG, Xiucheng PAN. Influencing factors for low-level viremia in chronic hepatitis B patients treated with long-term entecavir antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(3): 556-559. doi: 10.3969/j.issn.1001-5256.2021.03.011
    [10]Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
    [11]Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
    [12]Zheng WeiPing, Shen ZhongYang. Risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma and related control strategies[J]. Journal of Clinical Hepatology, 2019, 35(11): 2391-2395. doi: 10.3969/j.issn.1001-5256.2019.11.003
    [13]Liu HongJin, Bao ChunMei, Bai WenLin, Li YinYin, Rong GuangHua, Lu YinYing, Chen Yan, Liu Ze, Cheng JiaMin, Ceng Zhen. Risk factors for infectious complications in primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1033-1037. doi: 10.3969/j.issn.1001-5256.2018.05.021
    [14]Chang XiuJuan, Lu YinYing, Rong GuangHua, Liu Ze, Chen Yan, Xu GuiLin, Gao XuDong, Lou Min, Wang ChunPing, Yang YongPing, Ceng Zhen. Risk factors for vascular invasion of primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1038-1041. doi: 10.3969/j.issn.1001-5256.2018.05.022
    [15]Shi XinXing, Zhang YanQiong, Zhu Peng, Yan GuoHua, Zhang ZhangJiang, Wang YuMing. Prognostic risk factors in patients with hepatitis B virus- related acute- on- chronic liver failure[J]. Journal of Clinical Hepatology, 2016, 32(4): 700-705. doi: 10.3969/j.issn.1001-5256.2016.04.018
    [16]Ai YeQing, Zhang ChengHua, Liu HuiFang. Risk factors for postoperative pulmonary infection in patients with primary liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(7): 1334-1337. doi: 10.3969/j.issn.1001-5256.2016.07.024
    [17]Hu CaiXia, Zheng JiaSheng, Lin Wei, Cui ShiChang. Analysis of risk factors for early recurrence after microwave ablation for primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(2): 228-231. doi: 10.3969/j.issn.1001-5256.2015.020
    [18]Yin TianSheng, Yi YaYang, Mao XiXian, Li DeWei. Meta-analysis of risk factors for posthepatectomy liver failure in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1009-1014. doi: 10.3969/j.issn.1001-5256.2014.10.009
    [19]Gao Rui, Liu ZhongJing, Chen Fei, Gao Lei, Jiang ChuanWu. Multivariate regression analysis of risk factors for HBV-related primary liver cancer[J]. Journal of Clinical Hepatology, 2014, 30(4): 370-372. doi: 10.3969/j.issn.1001-5256.2014.04.021
    [20]Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(4)

    1. 杨瑞锋，陈红松. 再认识乙型肝炎病毒检验现状与慢性乙型肝炎临床诊治需求的距离. 中华检验医学杂志. 2025(01): 8-14 .
    2. 周小燕，庞博，张晏，丁显平. microRNA对乙型肝炎病毒相关肝癌诊断价值的Meta分析. 实用预防医学. 2023(02): 222-226 .
    3. 张文海. 温补脾肾方联合替诺福韦治疗脾肾两虚型慢性乙型肝炎的临床研究. 中国实用医药. 2022(02): 182-184 .
    4. 焦文鹏，侯琳，崔妹娟，焦文静，马鸣，张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义. 癌变·畸变·突变. 2021(06): 430-434 .

    Other cited types(3)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 17.8 %FULLTEXT: 17.8 %META: 72.7 %META: 72.7 %PDF: 9.5 %PDF: 9.5 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.6 %其他: 5.6 %其他: 0.7 %其他: 0.7 %Bengaluru: 0.3 %Bengaluru: 0.3 %Central District: 0.1 %Central District: 0.1 %China: 1.0 %China: 1.0 %India: 0.3 %India: 0.3 %Moldova Republic of: 0.3 %Moldova Republic of: 0.3 %Rochester: 0.1 %Rochester: 0.1 %Singapore: 0.2 %Singapore: 0.2 %United States: 0.1 %United States: 0.1 %三门峡: 0.2 %三门峡: 0.2 %上海: 6.6 %上海: 6.6 %东莞: 0.1 %东莞: 0.1 %东营: 0.1 %东营: 0.1 %中山: 0.1 %中山: 0.1 %丽水: 0.1 %丽水: 0.1 %保定: 0.1 %保定: 0.1 %北京: 4.4 %北京: 4.4 %南京: 0.3 %南京: 0.3 %南宁: 0.7 %南宁: 0.7 %南昌: 0.1 %南昌: 0.1 %南通: 0.4 %南通: 0.4 %南阳: 0.1 %南阳: 0.1 %印度泰米尔纳德: 0.1 %印度泰米尔纳德: 0.1 %厦门: 0.2 %厦门: 0.2 %台州: 0.1 %台州: 0.1 %吉安: 0.2 %吉安: 0.2 %哈尔滨: 0.2 %哈尔滨: 0.2 %哥伦布: 0.1 %哥伦布: 0.1 %大连: 0.6 %大连: 0.6 %天津: 1.2 %天津: 1.2 %太原: 0.1 %太原: 0.1 %宁波: 0.3 %宁波: 0.3 %安曼: 0.1 %安曼: 0.1 %安阳: 0.1 %安阳: 0.1 %宜昌: 0.3 %宜昌: 0.3 %宣城: 0.1 %宣城: 0.1 %宿州: 0.3 %宿州: 0.3 %岳阳: 0.2 %岳阳: 0.2 %巴音郭楞: 0.1 %巴音郭楞: 0.1 %常州: 0.2 %常州: 0.2 %常德: 0.1 %常德: 0.1 %广州: 1.2 %广州: 1.2 %张家口: 1.6 %张家口: 1.6 %徐州: 0.1 %徐州: 0.1 %成都: 0.5 %成都: 0.5 %新乡: 0.2 %新乡: 0.2 %新界: 0.2 %新界: 0.2 %昆明: 0.5 %昆明: 0.5 %晋中: 0.1 %晋中: 0.1 %晋城: 0.1 %晋城: 0.1 %杭州: 1.5 %杭州: 1.5 %桂林: 0.2 %桂林: 0.2 %武汉: 0.6 %武汉: 0.6 %水牛城: 0.1 %水牛城: 0.1 %汕头: 0.1 %汕头: 0.1 %沈阳: 0.2 %沈阳: 0.2 %泰安: 0.2 %泰安: 0.2 %洛杉矶: 0.2 %洛杉矶: 0.2 %洛阳: 0.1 %洛阳: 0.1 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 0.1 %深圳: 0.1 %深圳市罗湖区: 0.2 %深圳市罗湖区: 0.2 %深圳市龙岗区: 0.1 %深圳市龙岗区: 0.1 %温州: 0.1 %温州: 0.1 %湖州: 0.1 %湖州: 0.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %烟台: 0.2 %烟台: 0.2 %益阳: 0.1 %益阳: 0.1 %盐城: 0.3 %盐城: 0.3 %石家庄: 0.1 %石家庄: 0.1 %福州: 0.3 %福州: 0.3 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %芒廷维尤: 29.1 %芒廷维尤: 29.1 %芝加哥: 0.2 %芝加哥: 0.2 %莫斯科: 1.5 %莫斯科: 1.5 %衢州: 0.2 %衢州: 0.2 %西宁: 24.7 %西宁: 24.7 %西安: 0.4 %西安: 0.4 %许昌: 0.1 %许昌: 0.1 %贵阳: 0.3 %贵阳: 0.3 %赤峰: 0.1 %赤峰: 0.1 %辽阳: 0.1 %辽阳: 0.1 %运城: 1.3 %运城: 1.3 %邯郸: 0.1 %邯郸: 0.1 %郑州: 0.5 %郑州: 0.5 %重庆: 1.2 %重庆: 1.2 %长春: 0.9 %长春: 0.9 %长沙: 1.3 %长沙: 1.3 %长治: 0.1 %长治: 0.1 %阜阳: 0.1 %阜阳: 0.1 %青岛: 0.2 %青岛: 0.2 %香港: 0.2 %香港: 0.2 %驻马店: 0.5 %驻马店: 0.5 %黄冈: 0.1 %黄冈: 0.1 %其他其他BengaluruCentral DistrictChinaIndiaMoldova Republic ofRochesterSingaporeUnited States三门峡上海东莞东营中山丽水保定北京南京南宁南昌南通南阳印度泰米尔纳德厦门台州吉安哈尔滨哥伦布大连天津太原宁波安曼安阳宜昌宣城宿州岳阳巴音郭楞常州常德广州张家口徐州成都新乡新界昆明晋中晋城杭州桂林武汉水牛城汕头沈阳泰安洛杉矶洛阳济南海得拉巴深圳深圳市罗湖区深圳市龙岗区温州湖州湘潭漯河烟台益阳盐城石家庄福州美国伊利诺斯芝加哥芒廷维尤芝加哥莫斯科衢州西宁西安许昌贵阳赤峰辽阳运城邯郸郑州重庆长春长沙长治阜阳青岛香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (721) PDF downloads(94) Cited by(7)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1352]YesterdayPV[2703]TodayIP[154]TodayPV[252]Online[20]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return